Assessment of birth cohort screening of chronic hepatitis C in colorectal cancer screening patients in British Columbia [0.03%]
评估英属哥伦比亚省结直肠癌筛查患者中慢性丙型肝炎的出生队列筛查
Rojin Kaviani,Frank Y Chou,Chenxi He et al.
Rojin Kaviani et al.
Background: Since 2018, British Columbia (BC) has recommended chronic hepatitis C (HCV) screening for those born between 1945 and 1964, with a provincial prevalence of 2.31%. Combining HCV and colorectal cancer (CRC) scre...
Xin Mu,Ziran Meng,Ashley Stueck et al.
Xin Mu et al.
Sarcoidosis is a multi-organ inflammatory disease that can have hepatic involvement in up to 80% of cases. Rarely, sarcoidosis can manifest with only confined disease to the liver. While most patients with hepatic sarcoidosis are clinically...
The effect of first-wave COVID-19 restrictions on HCV testing in Alberta, Canada: A trend analysis from 2019 to 2022 [0.03%]
加拿大艾伯塔省2019年至2022年间COVID-19首轮限制措施对HCV检测的影响：趋势分析
L Alexa Thompson,Sabrina S Plitt,Ran Zhuo et al.
L Alexa Thompson et al.
Background: Prior to the COVID-19 pandemic, Alberta was on track to meet national HCV elimination targets by 2030. However, it is unclear how the pandemic has affected progress. Here, we aim to assess the impact of first-...
Effects of curcumin in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis [0.03%]
姜黄素对非酒精性脂肪肝病患者的影响：系统回顾和荟萃分析
Adnan Malik,Muhammad Malik
Adnan Malik
Background: Curcumin is an anti-inflammatory that is proposed to have a positive impact on patients with non-alcoholic fatty liver disease (NAFLD). We aim to assess the effects of curcumin in patients with NAFLD. ...
Exploring autoantibodies as predictors of severe fibrosis or cirrhosis in metabolic dysfunction associated with steatotic liver disease [0.03%]
探索自身抗体作为代谢功能障碍伴脂肪肝疾病严重纤维化或肝硬化的预测因子
Mariam Ragheb,Micah Grubert Van Iderstine,Gerald Minuk et al.
Mariam Ragheb et al.
Background: Metabolic dysfunction associated steatotic liver disease (MASLD) and metabolic dysfunction associated steatohepatitis (MASH) are rapidly growing public health concerns. Identifying predictive markers for advan...
' I just never wanted them to feel uncomfortable': Barriers to pharmacy-based identification and treatment of hepatitis C in Victoria, Canada [0.03%]
“我只是不希望他们感到不舒服”：加拿大维多利亚市基于药房的乙型肝炎识别与治疗障碍
Marion Selfridge,Tamara Barnett,Karen Lundgren et al.
Marion Selfridge et al.
Background: Canada is currently on target to reach the 2030 WHO goal of HCV elimination. Continued high rates of treatment are required to meet this goal. Novel models such as Tayside, Scotland pharmacy-based HCV screenin...
Natasha Chandok,Eric M Yoshida
Natasha Chandok
Decoding hepatorenal tyrosinemia type 1: Unraveling the impact of early detection, NTBC, and the role of liver transplantation [0.03%]
肝肾酪氨酸血症1型的解码：早期检测、NTBC和肝脏移植作用的影响剖析
Mohit Kehar,Moinak Sen Sarma,Jayendra Seetharaman et al.
Mohit Kehar et al.
Hepatorenal tyrosinemia type 1 (HT-1) is a rare autosomal recessive disease that results from a deficiency of fumaryl acetoacetate hydrolase (FAH), a critical enzyme in the catabolic pathway for tyrosine. This leads to the accumulation of t...
An open label feasibility study of a nutrition and exercise app-based solution in cirrhosis [0.03%]
肝硬化的营养和运动应用程序解决方案的开放性可行性研究
Kathleen P Ismond,Christofer Cruz,Ana Teresa Limon-Miro et al.
Kathleen P Ismond et al.
Background: Nutrition and exercise are the mainstay of therapy for the prevention and treatment of frailty in cirrhosis. This pilot study assessed feasibility of the online delivery of an app-based semi-supervised nutriti...
Alexandra Cohen,Fernando Alvarez
Alexandra Cohen
Background: Pediatric acute liver failure (PALF) is a potentially lethal and rapidly progressive clinical syndrome, with a large proportion of cases remaining indeterminate despite extensive investigations. ...